Cancer Therapy

You have full text access to this OnlineOpen article

Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response

  1. Valentina Zuco,
  2. Valentina Benedetti,
  3. Michelandrea De Cesare,
  4. Franco Zunino†,*

Article first published online: 12 AUG 2009

DOI: 10.1002/ijc.24819

Issue

International Journal of Cancer

International Journal of Cancer

Volume 126, Issue 5, pages 1246–1255, 1 March 2010

Additional Information

How to Cite

Zuco, V., Benedetti, V., De Cesare, M. and Zunino, F. (2010), Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response. Int. J. Cancer, 126: 1246–1255. doi: 10.1002/ijc.24819

Author Information

  1. Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy

  1. †

    Fax: +39-02-23902692

*Preclinical Chemotherapy and Pharmacology Unit, Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy

Publication History

  1. Issue published online: 27 DEC 2009
  2. Article first published online: 12 AUG 2009
  3. Accepted manuscript online: 12 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 3 AUG 2009
  5. Manuscript Received: 5 MAY 2009

Funded by

  • Associazione Italiana per la Ricerca sul Cancro, Milan
  • Fondazione CARIPLO, Milan
  • Fondazione Italo Monzino, Milan, Italy

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (879K)

References

  • 1
    Dallavalle S, Zunino F. Synthetic retinoids as potential antitumor agents. Expert Opin Ther Patents 2005; 15: 1625–35.
  • 2
    Garattini E, Gianni M, Terao M. Retinoid related molecules an emerging class of apoptotic agents with promising therapeutic potential in oncology: pharmacological activity and mechanisms of action. Curr Pharm Des 2004; 10: 433–48.
  • 3
    Pisano C, Vesci L, Foderà R, Ferrara FF, Rossi C, De Cesare M, Zuco V, Pratesi G, Supino R, Zunino F. Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models. Ann Oncol 2007; 18: 1500–5.
  • 4
    Lotan R. Receptor-independent induction of apoptosis by synthetic retinoids. J Biol Regul Homeost Agents 2003; 17: 12–28.
  • 5
    Zuco V, Zanchi C, Cassinelli G, Lanzi C, Supino R, Pisano C, Zanier R, Giordano V, Garattini E, Zunino F. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid. Cell Death Differ 2004; 11: 280–9.
  • 6
    Zanchi C, Zuco V, Lanzi C, Supino R, Zunino F. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer Res 2005; 65: 2364–72.
  • 7
    Zuco V, Zanchi C, Lanzi C, Supino R, Zunino F. Development of resistance to the atypical retinoid, ST1926, in the lung carcinoma cell line, H460 is associated with reduced formation of DNA strand breaks and a defective DNA damage response. Neoplasia 2005; 7: 667–77.
  • 8
    Valli C, Paroni G, Di Francesco AM, Riccardi R, Tavecchio M, Erba E, Boldetti A, Gianni M, Fratelli M, Pisano C, Merlini L, Antoccia A, et al. Atypical retinoids ST1926 and CD437 are S-phase-specific agents causing DNA double-strand breaks: significant for the cytotoxic and antiproliferative activity. Mol Cancer Ther 2008; 7: 2941–54.
  • 9
    Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin Cancer Res 2005; 11: 4912–22.
  • 10
    Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of γ-H2AX foci. Mol Cancer Ther 2006; 5: 1967–74.
  • 11
    Kim IA, Shin JH, Kim IH, Kim JH, Kim JS, Wu HG, Chie EK, Ha SW, Park CI, Kao GD. Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53. Clin Cancer Res 2006; 12: 940–9.
  • 12
    Chen C-S, Wang Y-C, Yang H-C, Huang PH, Kulp SK, Yang CC, Lu YS, Matsuyama S, Chen CY, Chen CS. Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Res 2007; 67: 5318–27.
  • 13
    Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M. Histone deacetylase enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 2008; 99: 376–84.
  • 14
    Geng L, Cuneo KC, Fu A, Tu T, Atadja PW, Hallahan DE. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to cytoplasm in irradiated non-small cell lung cancer. Cancer Res 2006; 66: 11298–304.
  • 15
    Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ. Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 2008; 14: 5410– 5.
  • 16
    Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 2005; 363: 15–23.
  • 17
    Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 1999; 18: 7644–55.
  • 18
    Cincinelli R, Dallavalle S, Nannei R, Carella S, De Zani D, Merlini L, Penco S, Garattini E, Giannini G, Pisano C, Vesci L, Carminati P, et al. Synthesis and structure-activity relationships of a new series of retinoid-related biphenyl-4-ylacrylic acids endowed with antiproliferative and proapoptotic activity. J Med Chem 2005; 48: 4931–46.
  • 19
    Dallavalle S, Cincinelli R, Nannei R, Merlini L, Morini G, Penco S, Pisano C, Vesci L, Barbarino M, Zuco V, De Cesare M, Zunino F. Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem 2009; 44: 1900–12.
  • 20
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556–62.
  • 21
    Benedetti V, Perego P, Beretta GL, Corna E, Tinelli S, Righetti SC, Leone R, Apostoli P, Lanzi C, Zunino F. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther 2008; 7: 679–87.
  • 22
    Drewinko B, Loo TL, Brown JA, Gottlieb JA, Freireich EJ. Combination chemotherapy in vitro with adryamicin. Observation of additive, antagonist and synergistic effects when used in two-drug combination on cultured human lymphoma cells. Cancer Biochem Biophys 1976; 1: 187–95.
  • 23
    Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (2nd edn). Br J Cancer 1998; 77: 1–10.
  • 24
    Shiloh Y. The ATM-mediated DNA-damage response: taking shape. Trends Biochem Sci 2006; 31: 402–10.
  • 25
    Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle 2007; 6: 931–42.
  • 26
    Iliakis G, Wang Y, Guan J, Wang H. DNA damage checkpoint control in cells exposed to ionizing radiation. Oncogene 2003; 22: 5834–47.
  • 27
    Fillingham J, Keogh M-C. Krogan NJ. γ-H2AX and its role in DNA double-strand break repair. Biochem Cell Biol 2006; 84: 568–77.
  • 28
    Kim Y-C, Gerlitz G, Furusawa T, Catez F, Nussenzweig A, Oh KS, Kraemer KH, Shiloh Y, Bustin M. Activation of ATM depends on chromatin interactions occurring before induction of DNA damage. Nat. Cell Biol 2009; 11: 92–6.
View Full Article (HTML) Get PDF (879K)